p53 alpha-Helix mimetics antagonize p53/MDM2 interaction and activate p53

Area of Science:

• Molecular Biology
• Medicinal Chemistry
• Oncology

Background:

• MDM2 overexpression/hyperactivation inactivates wild-type p53 in ~50% of human tumors.
• MDM2-p53 inhibition occurs via binding of p53's N-terminal alpha-helical peptide (residues 16-28) to MDM2's hydrophobic pocket.
• This interaction is a key target for developing anti-cancer therapeutics.

Purpose of the Study:

• To design and synthesize novel p53 alpha-helical peptide mimics.
• To evaluate the efficacy of these mimics in inhibiting MDM2-p53 binding and activating p53.
• To explore the therapeutic potential of terphenyl-based scaffolds for wild-type p53 tumors.

Main Methods:

• Design of p53 alpha-helical peptide mimics utilizing a terphenyl scaffold.
• In vitro assessment of MDM2-p53 binding inhibition using ELISA assays.
• In vivo evaluation of p53 activation and accumulation in cell culture models.

Main Results:

• Several terphenyl-based compounds demonstrated potent inhibition of MDM2-p53 binding in vitro, with IC50 values ranging from 10 to 20 micromol/L.
• These compounds effectively induced p53 accumulation and activation in cell culture at concentrations of 15 to 40 micromol/L.
• The identified compounds function as effective p53 alpha-helical peptide mimics.

Conclusions:

• Novel p53 alpha-helical peptide mimics based on a terphenyl scaffold show promise as inhibitors of the MDM2-p53 interaction.
• These compounds can activate the tumor suppressor p53 pathway.
• Terphenyl-based p53 mimetics represent a potential therapeutic strategy for cancers characterized by wild-type p53.